BioLineRx’s Market Collapse: From $2 ILA Peak to a 1 ILA Floor—What Investors Need to Know
BioLineRx’s stock plunges to 1 ILA, a 52‑week low, as a clinical‑stage biotech grapples with zero profits, shrinking market cap and investor doubt.
2 minutes to read
